Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
Open original sourceLoading market dashboard
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
Open original source